Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014-2019

Hee Soo Kim, Solene Engel, David Neveu, Yael Thollot, Philipp Oster, Kuhyun Yang, Hee Soo Kim, Solene Engel, David Neveu, Yael Thollot, Philipp Oster, Kuhyun Yang

Abstract

Background: Invasive meningococcal disease is a notifiable disease in the Republic of Korea. The meningococcal (groups A, C, Y, and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-DT, Menactra®) was licensed in the Republic of Korea in 2014. This post-marketing surveillance (PMS) observational study aims to assess the safety of MenACWY-DT administration of routine clinical care to individuals aged 9-23 months as a two-dose series at least 3 months apart and to individuals 2-55 years as a single dose.

Methods: The PMS observational study (NCT02864927) included participants aged 9 months to 55 years and who were given MenACWY-DT during routine healthcare visits. The study participants were followed-up for up to 30 days following vaccination (additional time was allowed for the visit or phone call to be conducted). Study outcomes included solicited and unsolicited adverse reactions, unexpected adverse events, and serious adverse events (SAEs).

Results: A total of 640 participants 9-23 months of age and 671 participants 2-55 years of age were eligible for safety analysis. Overall, AEs were reported by 35.3% of participants aged < 2 years and 45% of participants aged 2-55 years. Solicited adverse reactions were reported by 21.4% and 17.4% of participants aged < 2 years and 2-55 years, respectively. Unsolicited adverse reactions were reported by 26.1% and 37.9%, respectively. No vaccine-related SAEs occurred during the study. The AEs reported in Korean population were consistent with the known safety profile of MenACWY-DT, and most were of grade 1-2 in severity.

Conclusions: This study did not detect any unanticipated or new safety findings of concern with MenACWY-DT in either of the study age groups, and provides reassurance that MenACWY-DT can be used as part of routine immunization care for the prevention of invasive meningococcal disease.

Trial registration: ClinicalTrials.gov Identifier, NCT02864927.

Keywords: Adverse reactions or events; MCV4; MenACWY-DT; Menactra®; Meningococcal infections; Meningococcal vaccine; Safety; Vaccines.

References

    1. Kang JH, Miao Y, Lee S, Kim JH, Lee KY, Ma SH, et al. A survey of serum bactericidal antibodies against neisseria meningitidis serogroups A, C, W and Y in adolescents and adults in the Republic of Korea. Infect Chemother. 2016;48(1):12–19. doi: 10.3947/ic.2016.48.1.12.
    1. Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10).
    1. Lee H, Seo Y, Kim KH, Lee K, Choe KW. Prevalence and serogroup changes of Neisseria meningitidis in South Korea, 2010–2016. Sci Rep. 2018;8(1):5292. doi: 10.1038/s41598-018-23365-8.
    1. Kim HW, Lee S, Lee JH, Woo SY, Kim KH. Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults. J Korean Med Sci. 2019;34(23):e169. doi: 10.3346/jkms.2019.34.e169.
    1. DALYs GBD, Collaborators H, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191. doi: 10.1016/S0140-6736(15)61340-X.
    1. Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, et al. Meningococcal disease surveillance in the Asia–Pacific region (2020): the Global Meningococcal Initiative. Journal of Infection. 2020. (in press)
    1. Kim HW, Lee S, Kwon D, Cha J, Ahn JG, Kim KH. Characterization of Oropharyngeal Carriage Isolates of Neisseria meningitidis in Healthy Korean Adolescents in 2015. J Korean Med Sci. 2017;32(7):1111–1117. doi: 10.3346/jkms.2017.32.7.1111.
    1. Heo JY. Meningococcal Disease in Korea: an Epidemiologic Study of the Underestimated Infectious Disease. Infect Chemother. 2016;48(1):51–53. doi: 10.3947/ic.2016.48.1.51.
    1. Borrow R, Lee JS, Vazquez JA, Enwere G, Taha MK, Kamiya H, et al. Meningococcal disease in the Asia–Pacific region: findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34(48):5855–5862. doi: 10.1016/j.vaccine.2016.10.022.
    1. Kim SA, Kim DW, Dong BQ, Kim JS, Anh DD, Kilgore PE. An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia. BMC Infect Dis. 2012;12:310. doi: 10.1186/1471-2334-12-310.
    1. Menactra®Prescribing information. 2018. Available from: Accessed on 28 Jul 2020.
    1. Kim DS, Kim MJ, Cha SH, Kim HM, Kim JH, Kim KN, et al. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. Int J Infect Dis. 2016;45:59–64. doi: 10.1016/j.ijid.2016.02.010.
    1. Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine. 2018;36(16):2133–2138. doi: 10.1016/j.vaccine.2018.02.107.
    1. Hansen J, Zhang L, Klein NP, Robertson CA, Decker MD, Greenberg DP, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017;35(49 Pt B):6879–6884. doi: 10.1016/j.vaccine.2017.09.032.
    1. Fukushima S, Kikuchi H, Miyazu M, Hamada A, Ouchi K, Takagi H, et al. A safety and immunogenicity study of a single dose of a meningococcal (groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in healthy Japanese participants. Jpn J Infect Dis. 2018;71(6):402–407. doi: 10.7883/yoken.JJID.2017.277.
    1. Javadekar B, Ghosh A, Kompithra RZ, Awasthi S, Perminova O, Romanenko V, et al. Safety and immunogenicity of two doses of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in indian and russian children aged 9 to 17 months. Indian Pediatr. 2018;55(12):1050–1055. doi: 10.1007/s13312-018-1440-z.
    1. Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, et al. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra(R)) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005–2016. Vaccine. 2020;38(40):6291–6298. doi: 10.1016/j.vaccine.2020.07.039.
    1. Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016;34(44):5273–5278. doi: 10.1016/j.vaccine.2016.09.003.
    1. Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson J, et al. Meningococcal conjugate vaccine safety surveillance in the vaccine safety datalink using a tree-temporal scan data mining method. Pharmacoepidemiol Drug Saf. 2018;27(4):391–397. doi: 10.1002/pds.4397.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться